DECREASED CLEARANCE OF UREMIC AND MILDLY CARBAMYLATED LOW-DENSITY-LIPOPROTEIN

被引:65
作者
HORKKO, S [1 ]
HUTTUNEN, K [1 ]
KERVINEN, K [1 ]
KESANIEMI, YA [1 ]
机构
[1] UNIV OULU, BIOCTR OULU, OULU, FINLAND
关键词
ATHEROSCLEROSIS; CARBAMYLATION; CHRONIC RENAL FAILURE; LDL; LIPOPROTEINS; UREMIA;
D O I
10.1111/j.1365-2362.1994.tb00974.x
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Low-density lipoprotein (LDL) was in vitro carbamylated with potassium cyanate and the clearance was studied in man. A minor carbamylation of LDL decreased the clearance of LDL by 41% (94% of amino groups free) and by 18% (90% of amino groups free). When LDL was extensively carbamylated its clearance was substantially accelerated. Moreover, the clearance of LDL isolated from 14 haemodialysis patients (uremic-LDL) was studied in rabbits. Uraemic-LDL, injected into rabbits simultaneously with the LDL of a healthy control subject, was cleared more slowly than the control-LDL (difference in fractional catabolic rate -6.5%, P=0.02). We also examined the lipid peroxidation of the carbamylated LDL by measuring the amount of thiobarbituric-acid reactive substances (TBARS) and formation of conjugated dienes during exposure of carbamylated LDL to 5 mu M CU2(+). The carbamylated and native LDL had similar lipid peroxidation and propensity for oxidation. In summary, both the uraemic-LDL and minimally carbamylated LDL had a decreased clearance in vivo, which may contribute to the accelerated atherosclerosis in uraemic patients.
引用
收藏
页码:105 / 113
页数:9
相关论文
共 38 条
[1]
LIPID AND APOLIPOPROTEIN PROFILES OF UREMIC DYSLIPOPROTEINEMIA - RELATION TO RENAL-FUNCTION AND DIALYSIS [J].
ATTMAN, PO ;
ALAUPOVIC, P .
NEPHRON, 1991, 57 (04) :401-410
[2]
AVIRAM M, 1988, J BIOL CHEM, V263, P16842
[3]
REDUCTION IN CHOLESTEROL AND LOW-DENSITY LIPOPROTEIN SYNTHESIS AFTER PORTACAVAL-SHUNT SURGERY IN A PATIENT WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA [J].
BILHEIMER, DW ;
GOLDSTEIN, JL ;
GRUNDY, SM ;
BROWN, MS .
JOURNAL OF CLINICAL INVESTIGATION, 1975, 56 (06) :1420-1430
[4]
Buege J A, 1978, Methods Enzymol, V52, P302
[5]
NATIONAL REGISTRY OF LONG-TERM DIALYSIS PATIENTS [J].
BURTON, BT ;
KRUEGER, KK ;
BRYAN, FA .
JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1971, 218 (05) :718-&
[6]
LIPOPROTEIN(A) IS AN INDEPENDENT RISK FACTOR FOR CARDIOVASCULAR-DISEASE IN HEMODIALYSIS-PATIENTS [J].
CRESSMAN, MD ;
HEYKA, RJ ;
PAGANINI, EP ;
ONEIL, J ;
SKIBINSKI, CI ;
HOFF, HF .
CIRCULATION, 1992, 86 (02) :475-482
[7]
EHNHOLM C, 1986, J LIPID RES, V27, P227
[8]
EFFECT OF ANTIOXIDANTS ON OXIDATIVE MODIFICATION OF LDL [J].
ESTERBAUER, H ;
PUHL, H ;
DIEBERROTHENEDER, M ;
WAEG, G ;
RABL, H .
ANNALS OF MEDICINE, 1991, 23 (05) :573-581
[9]
HEMOGLOBIN CARBAMYLATION IN UREMIA [J].
FLUCKIGER, R ;
HARMON, W ;
MEIER, W ;
LOO, S ;
GABBAY, KH .
NEW ENGLAND JOURNAL OF MEDICINE, 1981, 304 (14) :823-827
[10]
FOLCH J, 1957, J BIOL CHEM, V226, P497